{"id":60102,"date":"2021-09-20T13:03:07","date_gmt":"2021-09-20T11:03:07","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=60102"},"modified":"2025-08-13T14:56:15","modified_gmt":"2025-08-13T12:56:15","slug":"emmes-standardizes-on-veeva-development-cloud-to-streamline-product-development","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/emmes-standardizes-on-veeva-development-cloud-to-streamline-product-development\/","title":{"rendered":"Emmes Standardizes on ³Ô¹Ï±¬ÁÏ Development Cloud to Streamline Product Development"},"content":{"rendered":"

Global CRO builds technology foundation to drive scalability, efficiency, and compliance<\/em><\/p>\n

ROCKVILLE, MD and BARCELONA, Spain \u2014 20 Sept. 2021 \u2014<\/strong> Emmes<\/a> and ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced that Emmes is standardizing on ³Ô¹Ï±¬ÁÏ Development Cloud<\/a> applications across functional areas to enable greater speed and compliance. The company will use applications in Vault Clinical<\/a>, Vault Quality<\/a>, and Vault Safety<\/a> suites to establish a technology foundation for delivering clinical research and pharmacovigilance services to its global customers.<\/p>\n

\u201cOur strategic partnership with ³Ô¹Ï±¬ÁÏ empowers us to streamline how we work, improve visibility and oversight, and run faster, more cost-effective research programs,\u201d said Dr. Christine Dingivan, chief executive officer at Emmes. \u201cUsing agile and scalable cloud solutions is a strategic priority for Emmes since we are growing rapidly and expanding into new markets. ³Ô¹Ï±¬ÁÏ Development Cloud will enhance collaboration with sponsors and sites and help us keep up with evolving regulatory requirements.\u201d<\/p>\n

Building on its experience across more than 2,000 clinical trials, Emmes is making significant investments in people and technology to deliver focused offerings for biopharmaceutical and public sector clients. Adopting ³Ô¹Ï±¬ÁÏ Development Cloud applications will enable them with real-time information on a single, connected platform to drive better cross-team visibility and execution. <\/p>\n

\u201cEmmes shares our vision of connected drug development and together, we\u2019re helping advance the industry toward better collaboration and speed across the product lifecycle,\u201d said Jim Reilly, vice president of ³Ô¹Ï±¬ÁÏ Vault R&D. \u201c³Ô¹Ï±¬ÁÏ Development Cloud eliminates system and process silos so companies can focus on innovation and accelerate the delivery of products to patients.\u201d<\/p>\n

Emmes is standardizing on clinical applications Vault CTMS<\/a>, Vault eTMF<\/a>, Vault Study Start-up<\/a>, and Vault Payments<\/a>, quality applications Vault QMS<\/a> and Vault QualityDocs<\/a>, and safety application Vault Safety<\/a>. Looking ahead, the company plans to add Vault Training<\/a>, Vault SafetyDocs<\/a>, and regulatory applications Vault Submissions<\/a>, Vault Submissions Publishing<\/a>, and Vault Submissions Archive<\/a>. <\/p>\n

Learn more about ³Ô¹Ï±¬ÁÏ Development Cloud at the upcoming ³Ô¹Ï±¬ÁÏ R&D and Quality Summit Connect<\/a>, 14 October 2021. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com\/Summit<\/a>.<\/p>\n

Additional Information<\/strong>
\nFor more on ³Ô¹Ï±¬ÁÏ Vault Development Cloud, visit: veeva.com\/DevelopmentCloud<\/a>
\nConnect with ³Ô¹Ï±¬ÁÏ on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a><\/p>\n

About Emmes<\/strong>
\nFounded in 1977, Emmes is a global, full-service clinical research organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company\u2019s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical, and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com<\/a>.<\/p>\n

About ³Ô¹Ï±¬ÁÏ Systems<\/strong>
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,100 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions, particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2021. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time. <\/p>\n

###<\/p>\n

Contact:<\/strong><\/p>\n

Deivis Mercado
\n³Ô¹Ï±¬ÁÏ Systems
\n925-226-8821
\ndeivis.mercado@veeva.com<\/a><\/p>\n

Jeremy Whittaker
\n³Ô¹Ï±¬ÁÏ Systems
\n+49 6950955486
\njeremy.whittaker@veeva.com<\/a><\/p>\n

Dana Dever
\nEmmes
\n301-251-1161
\nddever@emmes.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Global CRO builds technology foundation to drive scalability, efficiency, and compliance.<\/p>\n","protected":false},"featured_media":60178,"parent":0,"template":"","class_list":["post-60102","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-operations","resource-area-20-quality","resource-area-20-regulatory","resource-area-20-safety","resource-area-20-vault-platform-area","resource-product-20-qms","resource-product-20-qualitydocs","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/60102"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":1,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/60102\/revisions"}],"predecessor-version":[{"id":60181,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/60102\/revisions\/60181"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/60178"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=60102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}